EHEC Vaccine Antigen Discovery via In Silico Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against Enterohemorrhagic Escherichia coli (EHEC) O157:H7 primarily focus on well-characterized virulence factors, limiting the exploration of other potential antigenic proteins that could provide protective immunity, and there is a need for more effective vaccines to prevent severe human infections.
Innovation Solution
A genome-wide in silico search using comparative genomics and immunoinformatics identifies EHEC-specific antigens with high probability of exposure during infection, grouped by antigenicity, and tested as DNA vaccines in a murine model to induce immune responses and reduce bacterial colonization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If vaccines focus only on well-characterized virulence factors, then vaccine development is simpler and more targeted, but the exploration of other potential antigenic proteins is limited
Solution Approach 1:
The patent segments the EHEC proteome into multiple priority groups (high, medium, low) based on in silico predictions of antigenicity and exposure probability. This segmentation allows systematic exploration of diverse antigenic proteins beyond traditional virulence factors, while maintaining manageable vaccine development pathways for each priority tier.
Solution Approach 2:
The patent employs in silico screening to evaluate a large number of potential antigenic proteins (excessive action) beyond the limited set of well-characterized virulence factors. This computational approach allows broad exploration of antigenic diversity while filtering candidates to a manageable number for experimental validation, thus balancing comprehensiveness with practicality.
2Reliability
If more EHEC-specific antigens are identified and tested, then vaccine effectiveness may improve, but the complexity of vaccine development increases
Solution Approach 1:
The patent performs preliminary in silico screening and prioritization of EHEC antigens before experimental validation. By pre-evaluating proteins based on antigenicity predictions and exposure probability, the method filters the large proteome into high-priority candidates, reducing the number of proteins that require laborious in vivo testing while maintaining high potential efficacy.
Solution Approach 2:
The patent uses in silico computational methods as an intermediary between the EHEC proteome and experimental vaccine testing. This computational filtering layer identifies and prioritizes candidate antigens based on predicted properties, serving as a bridge that reduces the complexity of subsequent experimental validation while enriching for high-potency vaccine candidates.
3Adaptability or versatility
If genome-wide in silico search is used to identify antigens, then antigen discovery coverage is enhanced, but computational resources and time are increased
Solution Approach 1:
The patent segments the EHEC proteome analysis into multiple priority groups (high, medium, low) based on computational predictions. This segmentation allows the genome-wide search to be organized systematically, processing and evaluating proteins in tiers of predicted importance, which optimizes computational resource allocation and reduces overall processing time compared to uniform evaluation of all proteins.
Solution Approach 2:
The patent changes the evaluation parameters by using in silico predictions of antigenicity and exposure probability to prioritize antigens. By transforming the evaluation from exhaustive experimental testing to computational scoring based on multiple parameters, the method achieves comprehensive antigen discovery coverage while significantly reducing the time and resources required for initial candidate identification.
Data Source
AI summary
Certain embodiments are directed to compositions comprising EHEC-specific antigens. In certain aspects EHEC O157:H7-specific antigen(s) are used as components of immunogenic compositions and vaccines.